273 related articles for article (PubMed ID: 28609657)
1. ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer.
Mahajan K; Malla P; Lawrence HR; Chen Z; Kumar-Sinha C; Malik R; Shukla S; Kim J; Coppola D; Lawrence NJ; Mahajan NP
Cancer Cell; 2017 Jun; 31(6):790-803.e8. PubMed ID: 28609657
[TBL] [Abstract][Full Text] [Related]
2. Loss of Long Noncoding RNA
Ghildiyal R; Sawant M; Renganathan A; Mahajan K; Kim EH; Luo J; Dang HX; Maher CA; Feng FY; Mahajan NP
Cancer Res; 2022 Jan; 82(1):155-168. PubMed ID: 34740892
[TBL] [Abstract][Full Text] [Related]
3. Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting.
Sawant M; Mahajan K; Renganathan A; Weimholt C; Luo J; Kukshal V; Jez JM; Jeon MS; Zhang B; Li T; Fang B; Luo Y; Lawrence NJ; Lawrence HR; Feng FY; Mahajan NP
Sci Transl Med; 2022 Jun; 14(649):eabg4132. PubMed ID: 35704598
[TBL] [Abstract][Full Text] [Related]
4. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
[TBL] [Abstract][Full Text] [Related]
6. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
8. Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer.
Mahajan K; Coppola D; Rawal B; Chen YA; Lawrence HR; Engelman RW; Lawrence NJ; Mahajan NP
J Biol Chem; 2012 Jun; 287(26):22112-22. PubMed ID: 22566699
[TBL] [Abstract][Full Text] [Related]
9. Interaction between androgen receptor and coregulator SLIRP is regulated by Ack1 tyrosine kinase and androgen.
De Silva D; Zhang Z; Liu Y; Parker JS; Xu C; Cai L; Wang GG; Earp HS; Whang YE
Sci Rep; 2019 Dec; 9(1):18637. PubMed ID: 31819114
[TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
11. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
[TBL] [Abstract][Full Text] [Related]
12. Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7.
Shiota M; Fujimoto N; Imada K; Yokomizo A; Itsumi M; Takeuchi A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26857528
[TBL] [Abstract][Full Text] [Related]
13. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
Del Re M; Biasco E; Crucitta S; Derosa L; Rofi E; Orlandini C; Miccoli M; Galli L; Falcone A; Jenster GW; van Schaik RH; Danesi R
Eur Urol; 2017 Apr; 71(4):680-687. PubMed ID: 27733296
[TBL] [Abstract][Full Text] [Related]
14. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of
Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
[TBL] [Abstract][Full Text] [Related]
16. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D
Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514
[TBL] [Abstract][Full Text] [Related]
17. ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.
Wang J; Zou JX; Xue X; Cai D; Zhang Y; Duan Z; Xiang Q; Yang JC; Louie MC; Borowsky AD; Gao AC; Evans CP; Lam KS; Xu J; Kung HJ; Evans RM; Xu Y; Chen HW
Nat Med; 2016 May; 22(5):488-96. PubMed ID: 27019329
[TBL] [Abstract][Full Text] [Related]
18. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
19. CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression.
Deng C; Chen J; Guo S; Wang Y; Zhou Q; Li Z; Yang X; Yu X; Zhang Z; Zhou F; Han H; Yao K
World J Urol; 2017 Aug; 35(8):1213-1221. PubMed ID: 28105499
[TBL] [Abstract][Full Text] [Related]
20. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
